Compare Amgen, Inc. (AMGN) vs Fox Corp Class B (FOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Fox Corp Class B — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Fox Corp Class B trades at $48.23 (market cap $21.54B). The key difference: Amgen, Inc. is far larger — about 9.1× Fox Corp Class B's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | FOX | |
|---|---|---|
Market Cap | $196.12B | $21.54B |
Sector | Health | Media |
52-Week High | $388.16 | $67.76 |
52-Week Low | $271.18 | $44.39 |
Enterprise Value | $241.41B | $25.51B |
Dividend Yield | 2.77% | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FOX stock trades at $48.75, up 0.64% today, amid a bearish technical signal but strong fundamental performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $1.41. The company's 2025 revenue surged to $16.3B, driving net income to $2.26B, while cash flow turned positive at $1.03B. Key developments include the $22B Roku acquisition, highlighting strategic moves in streaming, though leverage concerns have pressured the stock, which is down 25% over four weeks as of June 26, 2026 (Zacks Investment Research).
The outlook balances robust fundamentals against near-term headwinds. Valuation appears attractive with a P/E of 12.83 and EV/EBITDA of 8.19, but integration risks from the Roku deal and bearish technical trends pose challenges. Analyst consensus is mixed (42.86% Buy, 47.62% Hold), suggesting cautious optimism for long-term growth driven by streaming expansion and advertising recovery, though volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
